Meredith Flowers, in Ward, AR - Medicare Physical Therapy Provider

Meredith Flowers, is a medicare enrolled "Physical Therapist" provider in Ward, Arkansas. She graduated from medical school in 2014 and has 10 years of diverse experience with area of expertise as Physical Therapy. She is a member of the group practice Allied Therapy And Consulting Services, Pa and her current practice location is 1500 Wilson Loop, Ward, Arkansas. You can reach out to her office (for appointments etc.) via phone at (501) 941-5630.

Meredith Flowers is licensed to practice in Arkansas (license number PT3894) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1114326550.

Contact Information

	Meredith Flowers,
	1500 Wilson Loop, Ward, AR 72176-8656
	(501) 941-5630
	Not Available

Healthcare Provider's Profile

Full Name	Meredith Flowers
Gender	Female
Speciality	Physical Therapy
Experience	10 Years
Location	1500 Wilson Loop, Ward, Arkansas
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Meredith Flowers graduated from medical school in 2014

NPI Data:

NPI Number: 1114326550
Provider Enumeration Date: 08/21/2014
Last Update Date: 08/21/2014

Medicare PECOS Information:

PECOS PAC ID: 0345655247
Enrollment ID: I20210225002586

Medical Identifiers

Medical identifiers for Meredith Flowers such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1114326550	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	PT3894 (Arkansas)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Allied Therapy And Consulting Services, Pa	5597094920	11

News Archive

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund's capital is from returning investors, and the fund's partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the initiation of two pivotal U.S. Phase III trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental (under the chin) fat.

Some consumers may not find Obamacare premiums affordable

Even as the Obama administration releases average premiums for insurance policies to be sold in each state exchange, some news outlets explore how affordable those options will be for certain groups of consumers.

Findings could influence ways to control bacterial growth on medical and other surfaces

A flexible tail allows swimming bacteria to thin the surrounding liquid and to free themselves when trapped along walls or obstacles.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Meredith Flowers allows following entities to bill medicare on her behalf.

Provider Name	Allied Therapy And Consulting Services, Pa
Provider Type	Part B Supplier - Clinic/group Practice
Provider Identifiers	NPI Number: 1134185937 PECOS PAC ID: 5597094920 Enrollment ID: O20190911000702

News Archive

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

Some consumers may not find Obamacare premiums affordable

Findings could influence ways to control bacterial growth on medical and other surfaces

A flexible tail allows swimming bacteria to thin the surrounding liquid and to free themselves when trapped along walls or obstacles.

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Meredith Flowers is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Meredith Flowers, 1500 Wilson Loop, Ward, AR 72176-8656 Ph: (501) 941-5630	Meredith Flowers, 1500 Wilson Loop, Ward, AR 72176-8656 Ph: (501) 941-5630

News Archive

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

Some consumers may not find Obamacare premiums affordable

Findings could influence ways to control bacterial growth on medical and other surfaces

A flexible tail allows swimming bacteria to thin the surrounding liquid and to free themselves when trapped along walls or obstacles.

Physical Therapist in Ward, AR

Holly Peters, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-588-3211
Mrs. Samantha Cavagnaro, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-941-5630
Beyond Boundaries, Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2195 Peyton Street, Ward, AR 72176 Phone: 501-941-5630
Nicole C Himmelman, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop Rd, Ward, AR 72176 Phone: 501-941-5630 Fax: 501-843-2270
Chloe Bass, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-588-3211 Fax: 501-353-2599
Whitney Bartley, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-941-5630

Meredith Flowers, - Medicare Physical Therapist in Ward, AR

Contact Information

Healthcare Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

Some consumers may not find Obamacare premiums affordable

Findings could influence ways to control bacterial growth on medical and other surfaces

Medicare Reassignments

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

Some consumers may not find Obamacare premiums affordable

Findings could influence ways to control bacterial growth on medical and other surfaces

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

Some consumers may not find Obamacare premiums affordable

Findings could influence ways to control bacterial growth on medical and other surfaces

Physical Therapist in Ward, AR